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Core evidence place in therapy summary for aprepitant in the prevention of chemotherapy-induced
nausea and vomiting
Outcome measure Evidence Implications
Patient-oriented evidence
Control of acute and 
delayed emesis
Clear Adding aprepitant to standard antiemetic therapy with dexamethasone plus a serotonin antagonist improves
control of emesis and reduces need for rescue medication in patients receiving moderately or highly 
emetogenic chemotherapy
Control of nausea Clear Adding aprepitant to standard antiemetic therapy with dexamethasone plus a serotonin antagonist reduces
symptoms of nausea in patients receiving moderately or highly emetogenic chemotherapy
Patient satisfaction Clear Patients more satisfied with their antiemetic therapy when aprepitant added; less impact of symptoms on 
daily activities
Economic evidence
Cost effectiveness Limited  Acquisition cost of aprepitant may be partially offset by savings in overall direct costs
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Abstract
Introduction: Chemotherapy-induced nausea and vomiting (CINV) represents a significant burden on patients and healthcare systems.
Despite the introduction of serotonin antagonists, many patients still experience CINV, particularly delayed symptoms occurring more
than 24 hours after chemotherapy. Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist approved for use with other
antiemetics to prevent CINV caused by moderately to highly emetogenic chemotherapy.
Aims: To review the evidence underlying the use of aprepitant to prevent CINV.
Evidence review: In patients receiving moderately and highly emetogenic chemotherapy, adding aprepitant to standard antiemetic
therapy with dexamethasone and a serotonin antagonist significantly improved control of CINV. The degree of control of delayed CINV
was particularly pronounced, and effectiveness was more likely to be maintained in multiple cycles compared with standard therapy.
Nausea was generally less frequent among patients taking aprepitant. More patients receiving aprepitant were satisfied with their
treatment and reported minimal/no impact of CINV on daily activities. Aprepitant appears to be well tolerated, with fatigue being the most
commonly reported adverse event. The drug is an inhibitor and inducer of cytochrome P450 (CYP) 3A4, resulting in contraindications
and caution with some concomitant medication. Limited economic evidence suggests that a proportion of the acquisition cost of
aprepitant may be offset by savings in overall direct costs of managing CINV. 
Place in therapy: The evidence supports the recommended use of aprepitant in clinical guidelines for the prevention of CINV due to
highly emetogenic chemotherapy, and its recently approved role in regimens with moderate risk. It is particularly useful for delayed
symptoms. 
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Aprepitant (Emend®, Merck) is a selective neurokinin-1 (NK1;
substance P) receptor antagonist, which was approved by the
Food and Drug Administration (FDA) for use with other
antiemetics in the prevention of nausea and vomiting in patients
with cancer receiving moderately or highly emetogenic
chemotherapy in October 2005 and in March 2003, respectively.
Aprepitant is believed to prevent emesis by blocking the binding
of substance P to NK1 receptors in the brain.
This article reviews the evidence for the place of aprepitant in the
prevention of the acute and delayed chemotherapy-induced
nausea and vomiting (CINV).
Methods
English language literature searches were conducted on June 30,
2006 in the following databases, searching from the beginning of
the database to date unless otherwise stated. The search strategy
was “aprepitant AND (nausea AND vomiting)” unless otherwise
stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966 to
date. Limits imposed “English,” “clinical trial,” “meta analysis,”
“randomized controlled trial,” “review,” “human,” for specificity
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
term “(aprepitant AND nausea and vomiting AND
chemotherapy) AND (LG=EN) AND ((clinical-trial#))”
• BIOSIS, http://www.datastarweb.com. Search term
“(aprepitant AND nausea and vomiting AND chemotherapy)
AND (LG=EN) AND (PT=MEETING-ABSTRACT)” 
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluations Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm. All three
databases searched together. All fields searched
• NHS HTA, http://www.ncchta.org
• National Guideline Clearinghouse, http://www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• Clinical trials databases, http://www.clinicaltrials.gov, and
http://www.clinicalstudyresults.org
Online abstracts from the following congresses were searched
using the search strategy terms “aprepitant” or “Emend”:
• American Society of Clinical Oncology (ASCO), all
conferences from 2000 to 2006, http://www.asco.org 
• European Society for Medical Oncology (ESMO), all
conferences from 2002 to 2005, http://www.esmo.org
Following hand searching and removal of articles unrelated to
CINV, duplicates, nonsystematic reviews, editorials, records of
study methodology, and pharmacokinetic studies, a total of 15 full
papers and six abstracts were included in the evidence base
(Table 1). 
Disease overview
Nausea and vomiting are among the most feared side effects of
cancer chemotherapy, with good reason. CINV can cause
dehydration, malnutrition, interrupt critical chemotherapy, and
significantly impair daily activities and quality of life. Electrolyte
imbalances causing muscle cramps, hypotension, and vital organ
damage can result from severe or prolonged CINV (Bender et al.
2002), as can fatigue and confusion. Occasionally, esophageal
tears are caused by frequent vomiting, and pneumonia results
from aspiration of vomit (Bender et al. 2002). Poor control of CINV
can also increase healthcare costs (Stewart et al. 1999).
Many factors influence the incidence of CINV. The emetogenic
potential of different drugs used in chemotherapy varies
considerably (Table 2), with cisplatin at doses higher than 50 mg/m2
causing emesis in almost all patients (Aguilar et al. 2005).
Patient characteristics also determine the likelihood of CINV, with
emesis occurring more frequently in younger patients, women,
and those with a history of motion sickness, and less likely in
patients with a history of alcohol abuse (Markman 2002).
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Category Number of records
Full papers Abstracts
Initial search 121 26
records excluded 107 21
records included 14 5
Additional studies identified 1 1
Total records included 15 6
Level 1 clinical evidence
(systematic review, meta analysis)
11
Level 2 clinical evidence (RCT) 13 1
Level ≥3 clinical evidence
trials other than RCT 0 3
case reports 1 0
Economic evidence 0 1
For definitions of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial. 
Table 1 | Evidence base included in the review17
There are three types of CINV: acute (within 24 hours after the
start of chemotherapy, persisting for a number of hours); delayed
(more than 24 hours after the end of chemotherapy, may persist
for days); and anticipatory (before chemotherapy is given, based
on prior experience). Acute CINV is generally assumed to present
within 1 or 2 hours, although agents such as cyclophosphamide
and carboplatin are often associated with emesis after 
8–10 hours (Markman 2002), and the emetic response to
cisplatin is most frequent and severe within 4–8 hours of
administration (Aguilar et al. 2005). Delayed CINV is perhaps
more distressing and burdensome than acute symptoms,
because the incidence is higher, it can last longer, and it is 
more likely to occur when the patient is at home following
chemotherapy (Markman 2002; Aguilar et al. 2005). Delayed
symptoms have been reported in approximately 40% of patients
who experience no acute CINV (Aguilar et al. 2005). Furthermore,
awareness of the extent of delayed CINV is often underestimated
by healthcare professionals (Aguilar et al. 2005). Delayed CINV 
is most common with cisplatin at doses >100 mg/m2 [in 60–89% 
of patients (Gralla et al. 1999; Aguilar et al. 2005)], followed 
by carboplatin, cyclophosphamide, and doxorubicin [in 20 to
30% of patients (Gralla et al. 1999; Markman 2002)]. Anticipatory
CINV is more likely in patients who have experienced emesis
earlier in their chemotherapy; up to 30% of such patients still 
have anticipatory symptoms in the fourth cycle of treatment
(Aguilar et al. 2005). 
The emetic process is complex, involving many central and
peripheral neuroreceptors and neurotransmitters including
dopamine, serotonin, and substance P. Ultimately, noxious stimuli
influence the vomiting center in the lateral reticular formation of
the brain, causing emesis. Although the precise mechanism of
CINV is not fully understood, it is now believed that acute emesis
is caused by peripheral serotonergic pathways, and delayed
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High
(emetogenic potential ≥90%)
Moderate
(emetogenic potential 30–90%)
Low
(emetogenic potential 10–30%)
Minimal
(emetogenic potential <10%)
Intravenous
Cisplatin Oxaliplatin Topotecan Bleomycin
Mechlorethamine Cytarabine >1 g/m2 Gemcitabine Busulfan
Streptozocin Carboplatin Liposomal doxorubicin 2-chlorodeoxyadenosine
Carmustine Ifosfamide Mitoxantrone Fludarabine
Cyclophosphamide >1500 mg/m2 Cyclophosphamide <1500 mg/m2 Docetaxel Vincristine
Dacarbazine Doxorubicin Paclitaxel Vinblastine
Epirubicin Etoposide Vinorelbine
Daunorubicin Teniposide Bevacizumab
Idarubicin Pemetrexed
Irinotecan Methotrexate
Mitomycin
Fluorouracil
Cytarabine <100 mg/m2
Bortezomib
Cetuximab
Trastuzumab
Oral
Hexamethylmelamine Cyclophosphamide Capecitabine Chlorambucil
Procarbazine Etoposide Fludarabine Hydroxyurea
Temozolomide L-phenylalanine mustard
Vinorelbine 6-thioguanine
Imatinib Methotrexate
Gefitinib
Table 2 | Emetogenic potential of chemotherapeutic agents [adapted from Herrstedt J, et al. ESMO minimum clinical recom-
mendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol. 2005;16(Suppl. 1):i77–i79, 
by permission of Oxford University Press]symptoms by centrally acting substance P acting on NK1
receptors (Fig. 1). Anticipatory CINV is caused by the patient
forming a psychologic association between chemotherapy and
nausea and vomiting, and is therefore difficult to control if
previous treatment has resulted in CINV. 
Current therapy options
The multifactorial nature of CINV makes it difficult to control,
therefore prevention is more effective than treatment.
Management is centered on prevention of acute emesis, which in
turn significantly reduces the incidence and severity of delayed
and anticipatory emesis (Gralla et al. 1999; Markman 2002).
Preventive therapy is based on a combination of agents that
affect the different pathophysiologic pathways underlying acute
and delayed emesis.
Several classes of antiemetic drugs are available, including
serotonin receptor antagonists (e.g. dolasetron, granisetron,
ondansetron, and palonosetron), corticosteroids (principally
dexamethasone), dopamine antagonists (e.g. metoclopramide,
prochlorperazine), and the NK1 receptor antagonist aprepitant.
Several evidence-based clinical practice guidelines are available
and are in broad agreement (Table 3). Serotonin antagonists and
corticosteroids have been the standard of care in the guidelines,
and the combination is effective in between 60 and 70% of
patients experiencing acute CINV (Viale 2005). Corticosteroids
alone are effective in up to 90% of patients receiving low or
moderately emetogenic chemotherapy (Markman 2002). Both
classes of drug are well tolerated, with headache and
constipation most often associated with serotonin antagonists,
and sleep disturbances with corticosteroids (Markman 2002;
Aguilar et al. 2005; Viale 2005). 
Metoclopramide remains a treatment option in the National
Comprehensive Cancer Network (NCCN) guidelines for delayed
CINV with moderately emetogenic chemotherapy and acute CINV
with low-risk chemotherapy, with prochlorperazine as an
alternative in the latter scenario. These guidelines also
recommend that diphenhydramine can be given with a dopamine
antagonist, to counter the potential for distressing extrapyramidal
adverse effects and sedation (Viale 2005). Dopamine antagonists,
which have long been the treatment of choice for CINV, are being
superseded by the newer more effective and better-tolerated
agents, and it has been recommended that their use should be
reserved for patients who fail to respond to serotonin antagonists
(Markman 2002).
Unmet needs
Acute CINV is still experienced by up to 40% of patients receiving
a serotonin antagonist plus dexamethasone before highly
emetogenic cisplatin chemotherapy (Gralla et al. 1999; Markman
2002; Viale 2005), and 15% of those receiving a noncisplatin-
based high-risk regimen (Gralla et al. 1999). The observation that
serotonin antagonists are less effective in preventing delayed CINV
led to the proposed pathophysiology (see Fig. 1). Between 44 and
53% of patients receiving highly emetogenic chemotherapy with
cisplatin ≥70 mg/m2 and preventive treatment with a serotonin
antagonist plus dexamethasone experienced delayed CINV
(Aguilar et al. 2005). There is also evidence that the protective
effect of a serotonin antagonist plus a corticosteroid wears off
during multiple cycles of chemotherapy (Soukop et al. 1992;
Sigsgaard et al. 1999, 2001). 
With moderately emetogenic chemotherapy, acute CINV can be
prevented in up to 90% of patients receiving a corticosteroid,
which also reduces the risk of delayed emesis (Gralla et al. 1999).
However, some chemotherapy of moderate emetogenic potential
has a greater tendency to cause delayed CINV, notably
carboplatin, cyclophosphamide, and doxorubicin (Gralla et al.
1999; Markman 2002). Furthermore, although cyclophosphamide
and doxorubicin individually are classified as being moderately
emetogenic, the likelihood of CINV increases when these agents
are combined, as they frequently are in the adjuvant treatment of
women with breast cancer (Grunberg et al. 2005). As mentioned
earlier, particular patient groups, such as women, are at higher risk
of CINV. The choice of preventive treatment for CINV is dependent
on the emetogenic potential of the chemotherapy and the
individual patient characteristics. There remains a need to improve
the management of CINV, particularly delayed symptoms in
response to multiple cycles of moderately emetogenic
chemotherapy in susceptible patients. A greater recognition of
CINV (particularly delayed symptoms) among healthcare
professionals, a realization that it can be effectively managed, and
improved compliance with clinical practice guidelines, which is
often poor (Mertens et al. 2003), are also factors that need to be
considered.
Rationale for aprepitant
Aprepitant was approved by the FDA in March 2003 for the
prevention of acute and delayed CINV with highly emetogenic
chemotherapy, and in October 2005 for use with moderately
emetogenic regimens. It is the first of a new class of agents, the
NK1 receptor antagonists, to be clinically available. Aprepitant is
thought to prevent emesis by blocking the binding of substance P
to NK1 receptors in the brain (Aguilar et al. 2005; Kris et al. 2005;
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NSCLC, nonsmall cell lung cancer; SCLC, small cell lung cancer
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Fig. 1 | Proposed mechanism and time course of chemotherapy-
induced nausea and vomiting with cisplatin 
[adapted from Expert Rev Anticancer Ther. 5(6), 963–972
(2005) with permission of Future Drugs, Ltd]19
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Viale  2005). By acting on another neuroreceptor implicated in
CINV rather than serotonin receptors, it therefore offers another
option for the management of this multifactorial condition.
Clinical evidence with aprepitant 
In the study of drugs that prevent CINV a number of endpoints
are used. These include control rates based on the number of
vomiting episodes (complete control=no emesis), use of rescue
antiemetic therapy, and the more subjective patient perceptions
of nausea measured by visual analog scale (VAS, with 0=no
nausea and 100=as bad as possible) and effect on quality of life
(QOL) using the Functional Living Index Emesis (FLIE)
questionnaire. Some investigators use combined secondary
endpoints including no vomiting, no rescue therapy, and no
significant nausea (VAS score <25) (complete protection), and
no vomiting, no rescue therapy, and no nausea (VAS score <5)
(total control). The evidence for the effectiveness of aprepitant
in controlling vomiting is primarily evaluated below using
complete response rates (no emesis and no rescue medication)
as this was the most frequently studied endpoint. Efficacy was
assessed for acute and delayed CINV.
Guideline Emetogenic potential Acute CINV Delayed CINV
ASCO (Kris et al. 2006) High Serotonin antagonist + dexamethasone + aprepitant 
before chemotherapy
Dexamethasone + aprepitant
Moderate: patients 
receiving anthracycline +
cyclophsophamide
Aprepitant + serotonin antagonist + dexamethasone 
before chemotherapy
Aprepitant
Moderate Serotonin antagonist + dexamethasone Serotonin antagonist or
dexamethasone
Low Dexamethasone No routine antiemetic
Minimal No routine antiemetic No routine antiemetic
ESMO (Herrstedt et al. 2005) High Serotonin antagonist + corticosteroid + aprepitant Corticosteroid + aprepitant
Moderate Serotonin antagonist + corticosteroid Serotonin antagonist or
corticosteroid
Low Single agent e.g. corticosteroid No routine antiemetic
Minimal No routine antiemetic No routine antiemetic
MASCC (Kris et al. 2005;
MASCC 2005)
High Serotonin antagonist + dexamethasone + aprepitant 
before chemotherapy
Dexamethasone + aprepitant
Moderate: patients 
receiving anthracycline +
cyclophsophamide
Serotonin antagonist + dexamethasone + aprepitant 
before chemotherapy (women specifically)
Dexamethasone or aprepitant
Moderate Serotonin
antagonist + dexamethasone in first course
Dexamethasone or serotonin
antagonist
Low Single agent e.g. corticosteroid None stated
Minimal No routine antiemetic None stated
NCCN (NCCN 2006) High Aprepitant + serotonin antagonist + dexamethasone ±
lorazepam before chemotherapy
Aprepitant  + dexamethasone ±
lorazepam before chemotherapy
Moderate: patients 
receiving anthracycline +
cyclophsophamide; select patients
receiving cisplatin, carboplatin,
doxorubicin, epirubicin, ifosfamide,
irinotecan, methotrexate
Aprepitant + serotonin antagonist + dexamethasone 
before chemotherapy
Aprepitant +
dexamethasone ± lorazepam
Moderate Serotonin antagonist + dexamethasone ± lorazepam Dexamethasone or
serotonin antagonist or
metoclopramide ±
diphenhydramine
Low Dexamethasone or prochlorperazine or metoclopramide ± diphenhydramine ± lorazepam
CINV, chemotherapy-induced nausea and vomiting.  
Table 3 | Evidence-based clinical practice guidelines for the prevention of acute and delayed chemotherapy-induced nausea 
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Thirteen randomized controlled trials (RCTs) published in full
were identified from the literature search, four of which were
subanalyses of pooled data from earlier studies (de Wit et al.
2004; Gralla et al. 2005; Warr et al. 2005a; Hesketh et al.
2006a). Two of the earlier trials (Campos et al. 2001; Van Belle
et al. 2002) have been criticized for using substandard
antiemetic prophylaxis, defined as patients not receiving a
serotonin antagonist plus a corticosteroid on the day of
chemotherapy administration for acute CINV, and either
treatment other than a corticosteroid or unspecified antiemetic
treatment for delayed CINV (Holdsworth & Vo-Nguyen 2005).
However, at the time these trials were conducted (1997 to
1998), there was no consensus on standard antiemetic
prophylaxis, which may explain the discrepancy (Van Belle et al.
2002). Two papers reported a trial investigating the efficacy of
aprepitant after one (Warr et al. 2005b) or multiple (Herrstedt et
al. 2005b) cycles of moderately emetogenic chemotherapy. For
all studies, modified intention to treat (mITT) was used for
efficacy analysis, defined as patients who received
chemotherapy, study drug, and had at least one posttreatment
assessment during a cycle.
Two systematic reviews were identified in the literature. A health
technology assessment of the limited evidence available in
2003 concluded that aprepitant appeared to offer a significant
advantage when added to standard antiemetic therapy with a
serotonin antagonist and a corticosteroid during highly
emetogenic chemotherapy (CCOHTA 2003). A meta analysis of
seven RCTs published between 1990 and 2003 on unspecified
NK1 receptor antagonists used with cisplatin 50 to 100 mg/m2
revealed a significant increase in complete responses to
delayed CINV, with no significant effect in the acute phase
(Tremont-Lukats et al. 2004).
While these systematic reviews represent level 1 evidence, they
have been superseded by full publication of level 2 evidence on
the efficacy of aprepitant, which is considered below. 
Control of CINV with highly emetogenic chemotherapy 
There is strong evidence for the efficacy of aprepitant in
combination with other antiemetics for the prevention of nausea
and vomiting caused by highly emetogenic chemotherapy with
cisplatin ≥70 mg/m2 (Table 4). 
One of the first trials demonstrated that the addition of aprepitant
400 mg on day 1 of chemotherapy significantly reduced the
frequency of both acute and delayed emesis compared with a
standard regimen of granisetron and dexamethasone (Campos et
al. 2001). This triple combination was also significantly more
effective than aprepitant plus dexamethasone alone for delayed
emesis, but not acute symptoms. Nausea control was similarly
better for the combination of aprepitant, granisetron, and
dexamethasone during acute and delayed phases. Nevertheless,
the combination of aprepitant plus dexamethasone, without
granisetron, provided some degree of protection against acute and
delayed CINV; administering a further dose of aprepitant the night
before chemotherapy conferred no additional benefit (Table 4). 
The efficacy of the dual combination of aprepitant plus
dexamethasone was confirmed by Van Belle et al. (2002).
Significantly more patients receiving the combination of
intravenous L-758,298 (the prodrug of aprepitant) plus
dexamethasone on day 1 followed by oral aprepitant on days 2
to 5 after chemotherapy achieved a complete response in the
delayed phase compared with patients receiving ondansetron
plus dexamethasone (Table 4). However, the converse was true
for the acute phase, with this combination being more effective
in controlling acute nausea and therefore having higher patient
satisfaction ratings (Table 5). Control of nausea symptoms in
the delayed phase was not significantly different among the
three groups. 
These trials used doses of aprepitant 400 mg or L-758,298
100 mg on day 1, and aprepitant 300 mg on days 2 to 5. 
A subsequent study investigated the efficacy of aprepitant 375 
or 125 mg on day 1 and 250 or 80 mg on days 2 to 5 added to
standard therapy with ondansetron 32 mg plus dexamethasone
20 mg on day 1 and dexamethasone 8 mg on days 2 to 5 during
single (Chawla et al. 2003) or multiple (de Wit et al. 2003) cycles
of highly emetogenic chemotherapy. However during this 
trial a pharmacokinetic interaction became apparent, with 
aprepitant resulting in an approximately two-fold increase in
dexamethasone plasma levels in healthy volunteers (Blum et al.
2003) (see Dosage, administration, and formulations). The higher
doses of aprepitant were therefore discontinued. Adding
aprepitant 125 mg on day 1 followed by 80 mg on days 2 to 5 to
a standard regimen of ondansetron plus dexamethasone resulted
in significantly improved rates of acute and delayed emesis
control, with complete response in 83 and 73% of patients,
respectively (Chawla et al. 2003). Control was also improved with
a lower dose regimen of aprepitant 40 mg on day 1 and 25 mg
on days 2 to 5, but only reached a significant difference 
from standard therapy during the delayed phase (Table 4). The
efficacy of aprepitant 125 mg (day 1) and 80 mg (days 2–5) was
sustained during six cycles of chemotherapy (de Wit et al. 2003). 
A complete response was achieved in 64% of patients in cycle 1
and 59% in cycle 6, compared with the significantly lower rates
of 49 and 34%, respectively, in patients receiving standard
antiemetic therapy (Table 4).
These early phase II studies therefore provided evidence 
of the efficacy of aprepitant added to standard antiemetic
therapy given during highly emetogenic cisplatin-based
chemotherapy. However, the dose of dexamethasone was not
adjusted to compensate for the elevation in levels caused by
aprepitant, optimal dosages of aprepitant were still being
defined, and administration of the drug for 5 days after
chemotherapy did not seem to provide any further clinical
benefit. Two phase III randomized, double-blind, parallel-
group studies were therefore designed to investigate the
efficacy of aprepitant at a dosage of 125 mg on day 1 and 
80 mg on days 2 to 3, with a concomitant downward
adjustment of dexamethasone dose to equate plasma levels
between patients receiving standard antiemetic therapy and
those receiving additional aprepitant (Hesketh et al. 2003; 
Poli-Bigelli et al. 2003).21
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Chemotherapy
regimen
Antiemetic treatment Outcome Reference
Acute phase Delayed phase
Complete
response
(%)a
Nausea (median
VAS scores;
0=none;
100=worst)
Complete
response
(%)a
Nausea (median
VAS scores;
0=none;
100=worst)
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Gra 10 mcg/kg + Dex 20 mg + Ap 400 mg
Day 2–5: Ap 300 mg 
(n=54)
77 0 52 (P<0.001) 1 (P=0.003) Navari et al. 1999
Day 1: Gra 10 mcg/kg + Dex 20 mg + Ap 400 mg
Day 2–5: Pla 
(n=54)
83 0 43 (P=0.003) 3
Day 1: Gra 10 mcg/kg + Dex 20 mg + Pla
Day 2–5: Pla 
(n=51)
57 (P=0.004
vs other two
groups
combined)
1 16 10
Cis-based
≥70 mg/m2,
1 cycle
Day –1: Pla
Day 1: Gra 10 mcg/kg + Dex 20 mg + Pla
Day 2–5: Pla 
(n=90)
51 7.5 22 7 Campos et al.
2001
Day –1: Pla
Day 1: Gra 10 mcg/kg + Dex 20 mg + Ap 400 mg
Day 2–5: Ap 300 mg 
(n=86)
75 (P<0.01) 1 (P<0.05) 41 (P<0.05) 2 (P<0.05)
Day –1: Ap 400 mg
Day 1: Dex 20 mg + Ap 400 mg + Pla
Day 2–5: Ap 300 mg 
(n=89)
44 8.5 39 (P<0.05) 3 (P<0.05)
Day –1: Pla
Day 1: Dex 20 mg + Ap 400 mg + Pla
Day 2–5: Ap 300 mg 
(n=86)
41 9.5 39 (P<0.05) 3
Cis-based
≥70 mg/m2,
1 cycle
Day 1: L-758,298 100 mg + Dex 20 mg
Day 2–5: Ap 300 mg 
(n=61)
44
11
59 (P<0.005) 5 Van Belle et al.
2002
Day 1: L-758,298 100 mg + Dex 20 mg
Day 2–5: Pla 
(n=58)
36 46 4
Day 1: Ond 32 mg + Dex 20 mg
Day 2–5: Pla 
(n=58)
83 (P<0.001
vs other two
groups
combined)
1 (P<0.005 vs
other two groups
combined)
38 1
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Ap 125 mg + Ond 32 mg + Dex 20 mg
Day 2–5: Ap 80 mg + Dex 8 mg 
(n=131)
83.2
(P<0.05)
NR 72.7 (P<0.01) NR Chawla et al. 2003
Day 1: Ap 40 mg + Ond 32 mg + Dex 20 mg
Day 2–5: Ap 25 mg + Dex 8 mg 
(n=119)b
75.6 NR 63.9 (P<0.01) NR
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–5: Dex 8 mg + Pla 
(n=126)
71.4 NR 45.2 NR
continued overleaf...
Table 4 | Level 2 evidence of outcomes achieved with aprepitant in the prevention of CINV due to highly emetogenic chemotherapy in
double-blind, multicenter, parallel-group RCTs (all P values vs standard therapy without aprepitant unless otherwise stated)
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Chemotherapy
regimen
Antiemetic treatment Outcome Reference
Acute phase Delayed phase
Complete
response
(%)a
Nausea (median
VAS scores;
0=none;
100=worst)
Complete
response (%)a
Nausea (median
VAS scores;
0=none;
100=worst)
Cis-based
≥70 mg/m2,
6 cycles
Day 1: Ap 125 mg + Ond 32 mg + Dex 20 mg
Day 2–5: Ap 80 mg + Dex 8 mg 
(n=81)b
NR NR Cycle 1: 64
(P<0.05)
Cycle 6 (n=27):
59 (P<0.05)
NR de Wit et al. 2003c
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–5: Dex 8 mg + Pla 
(n=86)
NR NR Cycle 1: 49
Cycle 6 (n=33):
34
NR
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=260)
89.2
(P<0.001)
90.6d 75.4 (P<0.001) 75.3d Hesketh et al. 2003
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla 
(n=261)
78.1 86.5d 55.8 68.5d
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=283)
82.8
(P<0.001)
NR 67.7 (P<0.001) 73d Poli-Bigelli et al.
2003
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla 
(n=286)
68.4 NR 46.8 65d
Cis-based
≥70 mg/m2,
6 cycles
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=547)
Cycle 1: 61e (P<0.001)
Cycle 6 (n=89): 59e (P<0.001)
de Wit et al. 2004f
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla 
(n=552)
Cycle 1: 46e
Cycle 6 (n=78): 40e
Cis-based
≥70 mg/m2,
+Cyc (87)
and/or Dox (74)g
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=520)
71 (P<0.005) NR 67 (P<0.005) NR Gralla et al. 2005f
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla 
(n=523)
49 NR 32 NR
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=547)
86 (P<0.001) 91d (P<0.01) 72 (P<0.001) 74d (P<0.05) Warr et al. 2005af
Day 1: Ond 32 mg + Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla 
(n=552)
73 85d 51 67d
Cis-based
≥70 mg/m2,
1 cycle
Day 1: Ap 125 mg + Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=484 in total)
87.7
(P=0.005)
NR 74.1 (P=0.004) NR Schmoll et al. 2006
Day 1: Ond 32 mg + Dex 20 mg
Day 2–4: Ond 8 mg bid + Dex 8 mg bid
79.3 NR 63.1 NR
aDefined as no vomiting or use of rescue medication; bPatients initially received aprepitant 375 mg on day 1 and 250 mg on days 2–5 but this arm discontinued due to emerging
pharmacokinetic data indicating effect on dexamethasone plasma concentrations; cExtension of Chawla et al. 2003; dPercentage of patients reporting no significant nausea (peak VAS <25);
eResults presented as “full protection” defined as no vomiting and no significant nausea (i.e. interfering with daily activities); fPooled analysis of Hesketh et al. 2003 and Poli-Bigelli et al. 2003;
gAnalysis limited to patients receiving these concomitant drugs. Other patients received etoposide, fluorouracil, gemcitabine, vinorelbine, paclitaxel, and docetaxel.
Ap, aprepitant; bid, twice daily; CINV, chemotherapy-induced nausea and vomiting; Cis, cisplatin; Cyc, cyclophosphamide; Dex, dexamethasone; Dox, doxorubicin; Gra, granisetron; NR, not
reported; Ond, ondansetron; Pla, placebo; RCT, randomized controlled trial; VAS, visual analog scale.
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These studies, which involved over 1000 patients, corroborate
the phase II evidence and demonstrate that addition of
aprepitant to a standard antiemetic regimen of a serotonin
antagonist plus a corticosteroid results in significantly greater
control of emesis, particularly in the delayed phase (Table 4).
Ondansetron 32 mg intravenously plus dexamethasone 20 mg
orally on day 1, followed by dexamethasone 8 mg twice daily on
days 2 to 4 gave complete response rates of 68 to 78% in the
acute phase, and 47 to 56% in the delayed phase, which is
consistent with previous clinical experience. Adding aprepitant
significantly improved acute complete response rates by 11 to
14% and delayed rates by 20%; overall, from days 1 to 5, the
improvement was 19 to 20%. All patients with no acute emesis
were also more likely to be emesis-free in the delayed phase, but
delayed emesis was less likely in the acute emesis-free
aprepitant recipients compared with those given standard
therapy according to both Hesketh et al. (2003) (13.7 vs 30.6%)
and Poli-Bigelli et al. (2003) (20.7 vs 35.4%). A subanalysis on
the pooled results of these studies reported delayed emesis
rates of 68% in the 13% of aprepitant recipients experiencing
acute emesis, compared with 85% of 26% in the control
group (Warr et al. 2005a). Similar numbers of patients
experienced an emetic episode in the first 12 hours of treatment,
and remained relatively consistent in the aprepitant
group. Vomiting occurred in approximately 20 patients
receiving aprepitant in each 4-hour interval up to 24 hours and
8-hour interval up to 5 days, in contrast to the patients receiving
standard therapy, 66 of whom vomited in the 20–24-hour
interval, reaching a peak of 80 patients in 40–48 hours (Warr et
al. 2005a). A similar pattern was observed for patients who
had >1 episode of vomiting. However, the number of
patients who had ≤5 or ≤3 emetic episodes were similar in both
aprepitant and standard therapy groups (65 vs 64%, and 49 vs
47%, respectively). 
A number of other subanalyses of the combined results of
Hesketh et al. (2003) and Poli-Bigelli et al. (2003) have been
published. One provides evidence that the benefits of adding
aprepitant are maintained through multiple cycles of
chemotherapy (de Wit et al. 2004), with complete response in the
sixth cycle in 59% of the aprepitant group, compared with 40%
for standard therapy (Table 4). Another looked at between-sex
differences in response. As mentioned earlier, women are at
higher risk of CINV than men, and this finding was also seen with
aprepitant, with lower response rates in female patients
compared with males (Hesketh et al. 2006a). However, women
receiving aprepitant had significantly better response rates than
those receiving standard therapy: 86 versus 66% in the acute
phase, and 70 versus 45% in the delayed phase. A further
analysis investigated the efficacy of adding aprepitant in patients
receiving moderately emetogenic chemotherapy with
cyclophosphamide and/or doxorubicin as well as cisplatin (Gralla
et al. 2005). Among this subgroup, complete responses were
seen during the acute and delayed phase in 71 and 67%,
respectively, of those receiving aprepitant (n=70) compared with
49 and 32% of those on standard antiemetics (n=72). Overall, the
response to aprepitant in this subset was greater than in the total
treatment population.
Feelings of nausea were also reduced by aprepitant (Table 4).
The combined analysis by Warr et al. (2005a) revealed a
significant improvement in favor of aprepitant for both acute and
delayed nausea scores. The rates for the combined endpoint of
complete protection (no emesis, no rescue antiemetic
medication, and no significant nausea defined as a score of
<25 mm on the VAS) was 55.6 and 63.4% for aprepitant versus
40.7 and 49.2% for standard therapy (P<0.01) (Hesketh et al.
2003; Poli-Bigelli et al. 2003). 
Administration of a serotonin antagonist on multiple days is
recommended in treatment guidelines to control delayed CINV
due to moderately, but not highly, emetogenic chemotherapy
(Table 3). Nevertheless, one study has compared an aprepitant
regimen (aprepitant, ondansetron, and dexamethasone on day 1;
aprepitant and dexamethasone on days 2 to 3; and
dexamethasone on day 4) with ondansetron and dexamethasone
given over 4 days in 484 patients receiving cisplatin ≥70 mg/m2
(Schmoll et al. 2006). Complete responses occurred in 88% of
the aprepitant group versus 79% with ondansetron in the acute
phase (P=0.005), and in 74 versus 63% (P=0.004) in the delayed
phase. Aprepitant has also been used as salvage therapy in 
29 patients refractory to standard antiemetic therapy, where it
decreased the proportion of patients experiencing emesis for
>2 days from 85 to 0%, and those with nausea for >4 days from
77 to 12%, although the frequency of acute nausea occurred in
16 patients (62%) (Bokemeyer et al. 2005).
Clearly, CINV can have a considerable negative effect on
patients’ wellbeing and day-to-day functioning. Using the FLIE
questionnaire, 74% of patients taking aprepitant reported
minimal or no impact on daily life, approximately 10% more than
those on standard antiemetics (Table 5).
There is limited level 4 evidence from two case reports that
aprepitant is effective in adolescent patients receiving highly
emetogenic chemotherapy, which is an observation worthy of
further study since younger patients are at greater risk of CINV
(Smith et al. 2005).
Control of CINV with moderately emetogenic chemotherapy
As mentioned above, the protective efficacy of aprepitant appears
to be greater in patients receiving moderately emetogenic
chemotherapy with cyclophosphamide and/or doxorubicin as
well as cisplatin, and women responded better than to standard
antiemetic treatment. There is also evidence from an abstract that
adding aprepitant to a standard regimen of palonosetron and
dexamethasone is effective in patients receiving moderately or
moderate to highly emetogenic chemotherapy with
cyclophosphamide plus doxorubicin, or paclitaxel plus
carboplatin (Grote et al. 2004; Table 6).
Consequently, the efficacy of aprepitant in preventing CINV
caused by moderately emetogenic regimens has been evaluated
in an RCT in 866 patients with breast cancer (all but two were
women) receiving cyclophosphamide with or without doxorubicin
or epirubicin (Warr et al. 2005b). Aprepitant 125 mg plus
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Chemotherapy
regimen
Antiemetic treatment Patient satisfaction/QOL rating Reference
Acute phase Delayed phase Overall
Highly emetogenic chemotherapy
Cis-based 
≥70 mg/m2, 1 cycle
Day 1: Gra 10 mcg/kg
+ Dex 20 mg + Ap 400 mg
Day 2–5: Ap 300 mg 
(n=54) 100a
NR 100a (P=0.001) Navari et al. 1999
Day 1: Gra 10 mcg/kg
+ Dex 20 mg + Ap 400 mg
Day 2–5: Pla 
(n=54)
NR 98a (P=0.03)
Day 1: Gra 10 mcg/kg 
+ Dex 20 mg + Pla
Day 2–5: Pla 
(n=51)
100a NR 82a
Cis-based 
≥70 mg/m2, 1 cycle
Day –1: Pla
Day 1: Gra 10 mcg/kg
+ Dex 20 mg + Pla 
Day 2–5: Pla 
(n=90)
94a NR 92a Campos et al. 2001
Day –1: Pla
Day 1: Gra 10 mcg/kg
+ Dex 20 mg + Ap 400 mg
Day 2–5: Ap 300 mg 
(n=86)
98a NR 95a
Day –1: Ap 400 mg
Day 1: Dex 20 mg +
Ap 400 mg + Pla
Day 2–5: Ap 300 mg 
(n=89)
96a NR 96a
Day –1: Pla
Day 1: Dex 20 mg
+ Ap 400 mg + Pla
Day 2–5: Ap 300 mg 
(n=86)
96a NR 98a
Cis-based 
≥70 mg/m2, 1 cycle
Day 1: L-758,298 100 mg
+ Dex 20 mg
Day 2–5: Ap 300 mg 
(n=61)
91a
92a NR Van Belle et al. 2002
Day 1: L-758,298 100 mg
+ Dex 20 mg
Day 2–5: Pla 
(n=58)
88a NR
Day 1: Ond 32 mg 
+ Dex 20 mg
Day 2–5: Pla 
(n=58)
99a (P<0.005 vs
other two groups
combined)
96a NR
Cis-based 
≥70 mg/m2, 1 cycle
Day 1: Ap 125 mg
+ Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=260)
NR NR 74% minimal/
no impactb
Hesketh et al. 2003
Day 1: Ond 32 mg 
+ Dex 20 mg + Pla 
Day 2–4: Dex 8 mg bid + Pla
(n=261)
NR NR 64.3% minimal/
no impactb
continued opposite...
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ondansetron and dexamethasone on day 1 followed by aprepitant
80 mg on days 2 and 3 produced more complete responses than
ondansetron plus dexamethasone alone on day 1 followed by the
serotonin antagonist on days 2 and 3 (Table 6). The difference
between antiemetic treatments was significant for acute CINV,
although control of nausea was comparable between groups. This
was reflected in the nausea domain in the FLIE assessment, with
no difference between groups, although overall significantly more
patients receiving aprepitant reported minimal or no impact on
daily living (63.5 vs 55.6%; P=0.019). In those patients who
experienced emesis, the time to first episode of vomiting was also
delayed by aprepitant.
An extension of this study provides evidence that the protective
effect of aprepitant is maintained over multiple cycles (Herrstedt
et al. 2005b). Among evaluable patients who had a complete
response in cycle 1, response was sustained in cycle 4 in 34.5%
of the aprepitant group and 23.9% of the standard therapy group
(Table 6). The difference was greatest in patients who experienced
no emesis, becoming progressively more pronounced by cycle 4.
The frequency of nausea was similar between groups, although
more aprepitant recipients reported lack of significant nausea, 
the difference being significant during cycle 2 (65.5 vs 56.9%;
P=0.02).
These positive results are still filtering their way into clinical
practice, although current guidelines do reflect the approval of
aprepitant for preventing CINV due to moderately emetogenic
chemotherapy (see Patient group/population). Many patients on
cyclophosphamide plus doxorubicin are still receiving a serotonin
antagonist plus dexamethasone. However, as discussed earlier, 
not all patients respond to this regimen, particularly over 
Chemotherapy
regimen
Antiemetic treatment Patient satisfaction/QOL rating Reference
Acute phase Delayed phase Overall
Cis-based 
≥70 mg/m2, 1 cycle
Day 1: Ap 125 mg +
Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=283)
NR NR 74.7% minimal/
no impactb
Poli-Bigelli et al. 2003
Day 1: Ond 32 mg 
+ Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla
(n=286)
NR NR 63.5% minimal/
no impactb
Cis-based 
≥70 mg/m2, 1 cycle
Day 1: Ap 125 mg + 
Ond 32 mg + Dex 12 mg
Day 2–3: Ap 80 mg + Dex 8 mg
Day 4: Dex 8 mg 
(n=547)
NR NR 74% minimal/
no impactb (P<0.01
vs standard therapy)
Warr et al. 2005ac
Day 1: Ond 32 mg 
+ Dex 20 mg + Pla
Day 2–4: Dex 8 mg bid + Pla
(n=552)
NR NR 64% minimal/
no impactb
Moderately emetogenic chemotherapy
Cyc 
750–1500 mg/m2
alone or Cyc 
500–1500 mg/m2
+ Dox ≤60 mg/m2 or
Epi ≤100 mg/m2,
4 cycles
Day 1: Ap 125 mg + 
Ond 8 mg + Dex 12 mg before
chemo and Ond 8 mg after 8 h
Day 2–3: Ap 80 mg 
(n=438)
NR NR 63.5% minimal/
no impactb (P=0.019 
vs standard therapy)
Warr et al. 2005b
Day 1: Ond 8 mg + 
Dex 20 mg + Pla before chemo
and Ond 8 mg after 8 h
Day 2–3: Ond 8 mg bid 
(n=428)
NR NR 55.6% minimal/
no impactb
aMedian global satisfaction VAS ratings (0=not at all satisfied; 100=completely satisfied); bFunctional Living Index Emesis (FLIE) questionnaire response; cPooled analysis of Hesketh et al. 
2003 and Poli-Bigelli et al. 2003.
Ap, aprepitant; bid, twice daily; CINV, chemotherapy-induced nausea and vomiting; Cis, cisplatin; Cyc, cyclophosphamide; Dex, dexamethasone; Dox, doxorubicin; Epi, epirubicin; Gra,
granisetron; h, hour; NR, not reported; Ond, ondansetron; Pla, placebo; QOL, quality of life; RCT, randomized controlled trial; VAS, visual analog scale.
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Level of
evidence
Design Chemotherapy
regimen
Antiemetic treatment Outcome Reference
Acute phase Delayed phase
Complete
response (%)a
Nausea (median
VAS scores;
0=none;
100=worst)
Complete
response (%)a
Nausea (median
VAS scores;
0=none;
100=worst)
2 DB, 
MC, PG
Cyc 
750–1500 mg/m2
alone or Cyc 
500–1500 mg/m2
+ Dox ≤60 mg/m2
or Epi
≤100 mg/m2,
4 cycles
Day 1: Ap 125 mg 
+ Ond 8 mg + Dex 12 mg
before chemo and Ond
8 mg after 8 h
Day 2–3: Ap 80 mg 
(n=438)
NR 0 Cycle 1: 50.8
(P=0.017)
Cycle 4 (n=344):
34.5 (P=0.017)
Cycle 1: 60.9b
Cycle 4 (n=344):
74.1b
Herrstedt et al.
2005bc
Day 1: Ond 8 mg 
+ Dex 20 mg + Pla
before chemo and Ond
8 mg after 8 h
Day 2–3: Ond 8 mg bid
(n=428)
NR NR Cycle 1: 42.5
Cycle 4 (n=307):
23.9 (P=0.017)
Cycle 1: 55.7b
Cycle 4 (n=344):
71.3b
2 DB, 
MC, PG
Cyc
750–1500 mg/m2
alone or Cyc
500–1500 mg/m2
+ Dox ≤60 mg/m2
or Epi 
≤100 mg/m2,
4 cycles
Day 1: Ap 125 mg 
+ Ond 8 mg + Dex 12 mg
before chemo and Ond
8 mg after 8 h
Day 2–3: Ap 80 mg
(n=438)
76 (P=0.034 
vs Pla)
NR 55 61b Warr et al. 2005b
Day 1: Ond 8 mg 
+ Dex 20 mg + Pla
before chemo and 
Ond 8 mg after 8 h
Day 2–3: Ond 8 mg bid
(n=428)
69 NR 49 56b
3 OL, MC Most common
regimens Dox 
+ Cyc and Pac 
+ Car (no further
details)
Day 1: Ap 125 mg 
+ Pal 0.25 mg 
+ Dex 12 mg 
Day 2–3: Ap 80 mg 
+ Dex 8 mg 
(n=39) 
90 80 Grote et al. 2004
3M C Dox ≤60 mg/m2 +
Cyc ≥500 mg/m2,
2 cycles
Day 1: Ond 8 mg, 
Dol 100 mg, or Gra 1 or
2 mg + Dex 8–10 mg
Day 2–3: Dex 4 mg bid 
(n=34; cycle 1)
32 0j 12 12j Hesketh et al.
2006b
Day 1: Ond 8 mg, Dol
100 mg, or Gra 1 or
2 mg + Dex 8–10 mg 
+ Ap 125 mg
Day 2–3: Dex 4 mg qd 
+ Ap 80 mg
(n=34; cycle 2)d
68 (P=0.01 vs
cycle 1)
21e 44 (P=0.02 vs
cycle 1)
3e
aDefined as no vomiting or use of rescue medication; bPercentage of patients reporting no significant nausea (peak VAS <25); cExtension of Warr et al. 2005b; dPatients continued to cycle 2,
with addition of aprepitant as salvage antiemetic therapy, if they failed to achieve complete control in cycle 1; ePercentage of patients reporting no significant nausea (4-point scale).
Ap, aprepitant; bid, twice daily; Car, carboplatin; CINV, chemotherapy-induced nausea and vomiting; Cyc, cyclophosphamide; DB, double-blind; Dex, dexamethasone; Dol, dolasetron; Dox,
doxorubicin; Epi, epirubicin; Gra, granisetron; h, hour; MC, multicenter; NR, not reported; OL, open-label; Ond, ondansetron; Pac, paclitaxel; Pal, palonosetron; PG, parallel-group; Pla, placebo;
qd, once daily; VAS, visual analog scale.
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multiple cycles. A phase II trial has investigated the use of a
prepitant as salvage therapy in patients receiving chemotherapy
with cyclophosphamide plus doxorubicin and refractory to
conventional antiemetic treatment with ondansetron plus
dexamethasone (Hesketh et al. 2006b). Thirty-four of 42 patients
(81%) did not achieve complete control (no emesis, no nausea,
and no rescue medications) to standard therapy in cycle 1 and
received additional aprepitant in cycle 2. Overall, seven patients
(21%) had complete control of their CINV with aprepitant, with
complete responses in 23 patients (68%) during the acute phase
and in 15 (44%) during the delayed phase (Table 6). Fewer
patients reported symptoms of delayed nausea with aprepitant,
although more experienced acute nausea. 
Tolerability
At least one adverse event occurred in 69% of 544 patients
receiving aprepitant to control CINV with highly emetogenic
chemotherapy, the most frequent being asthenia/fatigue (18%),
nausea (13%, considered to be drug-related if it occurred after day
5), hiccups (11%), anorexia (10%), constipation (10%), and
diarrhea (10%) (Warr et al. 2005a). Infections occurred in 12.5% of
patients, and 11.6% had a hematologic or lymphatic system
adverse event. The incidence of adverse events was similar to that
with standard therapy (Hesketh et al. 2003; Poli-Bigelli et al. 2003).
During multiple cycles, 6% of patients had an adverse event
related to aprepitant, 19% had serious clinical adverse events, and
12% discontinued treatment, a comparable pattern to that seen
with standard antiemetic treatment (de Wit et al. 2004).
In patients receiving aprepitant as protection against CINV caused
by moderately emetogenic chemotherapy, 21.5% experienced a
drug-related adverse event, considered serious in 3.4% and
necessitating discontinuation in 1.6% (Warr et al. 2005b). The
corresponding rates for standard therapy were 19.6, 4.2, and 1.2%.
There appeared to be slightly more dyspepsia in the aprepitant
group (8.4 vs 4.9%), and less constipation (12.3 vs 18%). During
repeated administration of aprepitant over two to four cycles, fatigue
(20.8%), alopecia (12.7%), constipation (9.9%), and headache
(9.4%) were the most common adverse events (Herrstedt et al.
2005b). Neutropenia was more frequent in the aprepitant group
compared with standard therapy (9.1 vs 5.8%), as was grade 
3–4 neutropenia (7 vs 3.6%), possibly as a result of greater exposure
to chemotherapy in the aprepitant group, although the difference did
not reach significance. Indeed, overall rates of febrile neutropenia
(2.9 vs 2.2%) and infection (17.1 vs 16.7%) were similar. 
Aprepitant is metabolized by cytochrome P450 (CYP) 3A4 in the
liver, and thus there is the potential for interactions with other
agents metabolized by this enzyme. The evidence for clinically
relevant interactions is contradictory. One study found a greater
incidence of serious adverse events in patients receiving
aprepitant and the CYP3A4-metabolized etoposide, vinca
alkaloids, and taxanes, compared with those on standard
antiemetic therapy (16 vs 8.5%) (Poli-Bigelli et al. 2003). In
contrast, however, no significant difference in adverse event 
profile was detected in aprepitant recipients compared with
standard therapy in patients who received chemotherapy with the
CYP3A4-metabolized drugs etoposide, vinorelbine, and paclitaxel
(Hesketh et al. 2003). Similarly, in a study in patients receiving
moderately emetogenic chemotherapy, no adverse events could
be attributed to interactions with aprepitant (Warr et al. 2005b).
However, caution should still be exercised and some drugs are
contraindicated due to the interaction potential of aprepitant 
(see Dosage, administration, and formulations, below).
Economic evidence
Available evidence specifically analyzing the cost effectiveness of
aprepitant is limited to two abstracts. One study describes a
Markov model that compared the then-standard ASCO antiemetic
therapy of a serotonin antagonist plus a corticosteroid, with
aprepitant plus standard therapy, or aprepitant added to a
standard therapy only after CINV occurs (Moore et al. 2005). The
model took a payer perspective, and included costs for resource
use for CINV management, Medicare reimbursement for hospital
and physician services, and average wholesale drug prices. Using
clinical trial data to model outcomes, the cost-effectiveness ratios
for each of the three regimens was $US13 907, $US41 060, and
$US27 619 per quality-adjusted life year (QALY), respectively.
Incremental cost-effectiveness ratios compared with standard
therapy alone were $US172 789 for aprepitant plus a
corticosteroid, and $US160 236 for adding aprepitant after CINV.
Aprepitant became cost effective at a cost of $US94 when added
to standard therapy in this model. The average wholesale price for
a course of aprepitant 125 mg on day 1 and 80 mg on days 2 and
3 is $US312 (Massaro & Lenz 2005). A decision analysis model
looking at NK1 receptor antagonists as a class, rather than
aprepitant specifically, estimated that to remain within a target
incremental cost-effectiveness threshold of $Can20 000 per 
QALY, the acquisition cost would have to be $Can6.60 (range
$Can4.80–10.00) per dose when added to granisetron and
dexamethasone after cisplatin-based chemotherapy (Dranitsaris
& Leung 2004). Assuming a regimen of NK1 antagonist being
given twice daily for 5 days, the total cost of a course would be
$Can66.00 (range $Can48.00–100.00). Clinical data for the model
were taken from a trial of the NK1 receptor antagonist CJ-11,974.
A cost-consequence study found that the costs of an aprepitant-
containing regimen were $US536 154 compared with 
$US238 982 for standard antiemetic therapy in a hypothetical
cohort of 1000 patients receiving a single cycle of highly
emetogenic chemotherapy (Bell et al. 2004). However, over the
course of 7 days after chemotherapy, total medical costs were
$US282 948 versus $US457 272, reflecting the greater efficacy 
of aprepitant.
These cost-effectiveness analyses, while giving an insight into the
economic consequences from a payer perspective, nevertheless
overlook patients’ willingness to pay for an improved quality of life
and relief from a distressing side effect of chemotherapy. This
aspect has been investigated for NK1 receptor antagonists as a
class. Patients from Spain, Canada, Italy, and Greece said they
would pay a maximum of $US63, $US46, $US34, and $US8 per
day (in 2000 $US), respectively, for a 20% reduction in acute
emesis (Dranitsaris et al. 2001a). The corresponding values
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Resource utilization 
Costs associated with the management of CINV are significant. 
A Canadian study involving 92 patients receiving antiemetic
prophylaxis with dexamethasone plus metoclopramide and other
antiemetics excluding serotonin antagonists, most of whom
(66%) were on moderately emetogenic chemotherapy, found that
additional nursing time and hospital admission represented the
largest single extra cost components, at $Can16.50 and
$Can24.90 per patient, respectively (O’Brien et al. 1993). These
costs were mainly from 72 patients who experienced CINV:
$Can17.80 (42 hours of nursing time) and $Can31.90 (9 hospital
days) per patient, with a total additional cost per patient of
$Can63.00. Importantly, indirect costs of CINV were $Can184.30
per patient, mainly through lost productivity. 
Similar results have been reported in Europe, with healthcare
resources (mainly rescue medication and physician and hospital
visits) used by 68 of 188 patients receiving 208 cycles of
moderate to highly emetogenic chemotherapy (Ihbe-Heffinger et
al. 2004). CINV occurred in 134 cycles, with the components of
direct cost incurred by third party payers (in 2002 currency, per
cycle per patient) being medication to prevent CINV (€45.37), treat
CINV (€11.20), hospitalization due to CINV (€5.34), physician
visits due to CINV (€4.65), and ambulance transport (€3.04). Other
direct costs borne by each patient per cycle amounted to €4.64,
and included other-the-counter medications, transport, and
childcare; indirect costs through loss of productivity were €3.05.
Across all 208 cycles, corresponding direct costs of treating and
preventing CINV per patient per cycle were €48.66, €2.99 for
other direct costs, and €1.97 in indirect costs. 
From the perspective of a US office-based oncologist, treatment
of an episode of CINV was estimated to incur $US175 in labor
costs (adjusted to 2005 $US), with an average reimbursement of
approximately $US198, based on the Centers for Medicare and
Medicaid Services 2005 reimbursement system (Vanscoy et al.
2005). This difference of $US23 represents net revenue for a
practice, but does not include costs associated with rent or other
overheads, indicating the potential economic impact of an
uncontrolled episode of CINV at this level.
The costs attributed to treating CINV could potentially be offset by
improved prophylaxis. This has been demonstrated for
ondansetron, where the higher incremental cost associated with
its use was offset by savings in nursing and pharmacy time,
hospital stay, and costs of supplies (Stewart et al. 1999). It may be
expected that the efficacy of aprepitant may similarly translate
into improved resource utilization. The economic evidence for
aprepitant gives an insight into its potential cost effectiveness that
takes into account costs of treating CINV, resource utilization, and
Medicare costs. A cost-consequence study that included costs
for aprepitant plus standard antiemetics for a hypothetical group
of 1000 patients receiving a single cycle of highly emetogenic
chemotherapy concluded that savings in overall direct medical
costs would offset 58.7% (range 20–80%) of the incremental cost
of adding aprepitant (Bell et al. 2004). Further cost savings could
possibly be realized by changing chemotherapy regimens (e.g.
giving shorter, more intensive cycles), as this has been
demonstrated for ondansetron (Stewart et al. 1999).
Patient group/population
Aprepitant (Emend) is approved for use with other antiemetic
drugs to prevent CINV in patients receiving initial and multiple
cycles of highly and moderately emetogenic chemotherapy
(Anon. 2006), based on the evidence from RCTs. Aprepitant is
established in ASCO, ESMO, Multinational Association for
Supportive Care in Cancer (MASCC), and NCCN guidelines for
patients on highly emetogenic chemotherapy, and in ASCO,
MASCC, and NCCN guidelines for those on an anthracycline
plus cyclophosphamide (Table 3). These recommendations will
have to be actively implemented in the clinic using pharmacist
intervention and education of physicians, as compliance with
evidence-based guidelines in the prevention of CINV is often
inconsistent (Italian Group for Antiemetic Research 1998;
Dranitsaris et al. 2001b). 
Aprepitant appears to be particularly useful in preventing
delayed CINV, and in women, who are at higher risk of CINV.
Aprepitant has been shown to be effective in small numbers of
adolescents receiving highly emetogenic chemotherapy, but this
requires confirmation in larger studies or groups of patients.
Dosage, administration, and formulations
The recommended dosage of aprepitant is 125 mg orally 1 hour
before chemotherapy on day 1, followed by 80 mg orally once
daily in the morning on days 2 and 3 (Anon. 2006). The drug is
available in a combination pack containing one 125 mg and two
80 mg capsules. Dosage adjustment is not necessary in patients
with mild to moderate hepatic insufficiency, impaired renal
function, or the elderly. 
Because it acts as an inhibitor and inducer of CYP3A4, aprepitant
should not be taken by patients receiving pimozide, cisapride,
terfenadine, and astemizole, and women of child-bearing age taking
oral contraceptives containing ethinyl estradiol and norethindrone
should use alternative methods of contraception during and
1 month after treatment with aprepitant. Patients taking warfarin
should have international normalized ratio of prothrombin time
monitored for 2 weeks following aprepitant treatment. The dosage
of dexamethasone and oral methylprednisolone as concomitant
antiemetic therapy needs to be reduced by approximately 50% with
aprepitant, and that of intravenous methylprednisolone by
approximately 25%. Aprepitant may also reduce the plasma
concentrations of phenytoin, and increase concentrations of the
benzodiazepines midazolam, alprazolam, and triazolam. Caution is
also advised when giving concomitant inhibitors of CYP3A4 (such
as ketoconazole, itraconazole, clarithromycin, ritonavir, and
nelfinavir) which may increase aprepitant concentrations, and with
inducers of CYP3A4 (such as rifampin, carbamazepine, and
phenytoin) which may reduce its concentration.
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Place in therapy
CINV presents a considerable burden on patients receiving
chemotherapy and on healthcare systems in terms of additional
costs. Despite the introduction of the serotonin receptor
antagonists and their adoption in clinical guidelines, CINV
remains poorly controlled in a significant number of patients,
particularly delayed symptoms caused by highly emetogenic
drugs, notably cisplatin. Part of this problem stems from poor
compliance with guidelines, but the efficacy of existing treatments
is also an issue. Furthermore, some moderately emetogenic
chemotherapy regimens are actually more likely to cause CINV,
and some particular patient groups are at higher risk. Perhaps the
best example is the use of adjuvant anthracyclines plus
cyclophosphamide in women with breast cancer.
Aprepitant is the first NK1 receptor antagonist to be approved 
for use in combination with other antiemetics to prevent CINV
caused by highly and moderately emetogenic chemotherapy. 
It has established its place in therapy in highly emetogenic
regimens, as it has been integrated into the practice guidelines 
of ASCO, ESMO, MASCC, and NCCN (Table 3). The evidence 
for its utility in moderate-risk chemotherapy is also being
translated into practice, with its recommendation for use by
MASCC and NCCN in patients receiving anthracyclines and
cyclophosphamide. As mentioned earlier, these evidence-based
clinical guidelines will need to be actively promoted to ensure
compliance and recognize the clinical benefits of the drug. 
There is evidence that a substantial proportion of the acquisition
cost of aprepitant can be offset by savings in the overall
management of CINV. Furthermore, the evidence gained with the
serotonin antagonists indicate that, when properly managed and
utilized, advances in antiemetic prophylaxis can save costs in
healthcare systems.
The final point that should be made regarding the place of
aprepitant is the effect on patient wellbeing. The evidence shows
a decrease in episodes of vomiting, use of rescue medication, 
and feelings of nausea when aprepitant is added to standard
antiemetic regimens. This efficacy translates into improved
patient satisfaction, which is a key consideration in the overall
management of patients with cancer.
In summary, aprepitant adds to the clinician’s ability to effectively
prevent CINV in a greater proportion of patients receiving
chemotherapy with moderate or high emetogenic potential.
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